Appetite Reduction Research Articles

Hypothalamic Hyperphagia in the Hospice Patient: Case Report and Discussion

We present a case of insatiable appetite and harmful overeating in a hospice patient that showcases the burden of hypothalamic hyperphagia, a rare complication of brain cancer. While confounders exist such as progression of disease and prior tapering of dexamethasone, in this case the initiation of metformin was associated with substantial appetite reduction and resolution of our patient's debilitating food-seeking behaviors.We will explore metformin as a potential cost-effective option for palliation in a hospice setting and explore some of the physiologic mechanisms involved.

EFEITOS DE FÁRMACOS PSICOTRÓPICOS NO TRATAMENTO DE DISTÚRBIOS COMPORTAMENTAIS EM CÃES (CANIS FAMILIARIS)

With the strengthening of human-animal interaction and the scientific recognition of sentience, there has been a significant increase in the perception of atypical behaviors in companion animals, as observed by legal guardians and veterinarians. In general terms, such changes occur due to excessive humanization, stress, fear, or inappropriate environments, leading to variations in temperament, emotional dependency, and/or inhibition of species-specific natural behaviors. The class of psychotropic drugs offers pharmacological treatment for the mental state of these animals by modulating neurotransmitters such as serotonin and dopamine. The objective of this study was to evaluate the pharmacological impact of psychotropic drugs on the social development and emotional resilience of these animals, in conjunction with behavioral therapy. For this purpose, domestic dogs (Canis familiaris) diagnosed with compulsive disorders secondary to other behavioral dysfunctions were treated with trazodone hydrochloride (Group 1) and extracts from Psilocybe cubensis mushrooms (Group 2), and compared to conventional treatment with fluoxetine hydrochloride. The animals were diagnosed and evaluated using questionnaires aimed at diagnosing and monitoring the evolution of treatment, based on the literature referenced in this study. Atypical behaviors associated with primary and secondary disorders were mitigated or eliminated in Group 1 (n=4), Group 2 (n=4), and the conventional treatment group. However, fluoxetine hydrochloride showed a reduction in appetite as a side effect.

Effects of Open-Label Placebos on Visual Food Cue Reactivity in Children and Adolescents

Background: A high level of food cue reactivity (FCR) is a risk factor for overeating and weight gain. This randomized trial investigated whether open-label placebos (OLPs: placebos honestly administered) can reduce FCR (reported appetite) in children and adolescents. Method: Children (n = 73; 8–12 years old) and adolescents (n = 187; 16–18 years old) were randomly assigned to either an OLP group or a control group (without OLP). Participants viewed images depicting food (sweets and fruits) and non-food items. Before viewing, the OLP group received a placebo for appetite reduction. Participants rated their desire to eat the depicted food items (0–100) and the perceived effectiveness of the OLP intervention. Results: The OLP exhibited a large effect in children, leading to a general reduction in appetite (group difference OLP vs. no OLP: M = −20.8; ηp2 = 0.20). This general effect was absent in adolescents, whose appetite reduction was restricted to fruits (OLP vs. no OLP: M = −8.1; ηp2 = 0.03). Additionally, children perceived the OLP as more effective than adolescents. Conclusion: The reduced response and skeptical attitudes of adolescents towards OLP treatment require further investigation.

Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study.

Introduction: Obesity is one of the major healthcare challenges. It affects one in eight people around the world and leads to several comorbidities, including type 2 diabetes, hyperlipidemia, and arterial hypertension. GLP-1 analogs have become major players in the therapy of obesity, leading to significant weight loss in patients. However, benefits resulting from their usage seem to be greater than simple appetite reduction and glucose-lowering potential. Recent data show better cardiovascular outcomes, which are connected with the improvements in the course of atherosclerosis. Macrophages are crucial cells in the forming and progression of atherosclerotic lesions. Previously, it was shown that in vitro treatment with GLP-1 analogs can affect macrophage phenotype, but there is a paucity of in vivo data. Objective: To evaluate the influence of in vivo treatment with liraglutide on basic phenotypic and functional markers of macrophages. Methods: Basic phenotypic features were assessed (including inducible nitric oxide synthase, arginase 1 and mannose receptors), proinflammatory cytokine (IL-1β, TNFα) release, and oxidative stress markers (reactive oxygen species, malondialdehyde) in macrophages obtained prior and after 3-month therapy with liraglutide in patients with obesity. Results: Three-month treatment with subcutaneous liraglutide resulted in the alteration of macrophage phenotype toward alternative activation (M2) with accompanying reduction in the TNFα release and diminished oxidative stress markers. Conclusions: Our results show that macrophages in patients treated with GLP-1 can alter their phenotype and function. Those findings may at least partly explain the pleiotropic beneficial cardiovascular effects seen in subjects treated with GLP-1 analogs.

Perspectives on obesity imaging: [18F]2FNQ1P a specific 5-HT6 brain PET radiotracer.

Estimates suggest that approximatively 25% of the world population will be overweight in 2025. Better understanding of the pathophysiology of obesity will help to develop future therapeutics. Serotonin subtype 6 receptors (5-HT6) have been shown to be critically involved in appetite reduction and weight loss. However, it is not known if the pathological cascade triggered by obesity modifies the density of 5-HT6 receptors in the brain. Influence of diet-induced obesity (DIO) in Wistar rats was explored using MRI (whole-body fat) and PET ([18F]2FNQ1P as a specific 5-HT6 radiotracer). The primary goal was to monitor the 5-HT6 receptor density before and after a 10-week diet (DIO group). The secondary goal was to compare 5-HT6 receptor densities between DIO group, Wistar control diet group, Zucker rats (with genetic obesity) and Zucker lean strain rats. Wistar rats fed with high-fat diet showed higher body fat gain than Wistar control diet rats on MRI. [18F]2FNQ1P PET analysis highlighted significant clusters of voxels (located in hippocampus, striatum, cingulate, temporal cortex and brainstem) with increased binding after high-fat diet (p < 0.05, FWE corrected). This study sheds a new light on the influence of high-fat diet on 5-HT6 receptors. This study also positions [18F]2FNQ1P PET as an innovative tool to explore neuronal consequences of obesity or eating disorder pathophysiology.

Fish production, water quality, and the role of nitrification as an ammonia removal process in intensively aerated hybrid catfish ponds

AbstractSix 0.1‐ha earthen ponds with 45 kW/ha of aeration capacity were stocked with hybrid catfish (Ictalurus punctatus x I. furcatus) ranging from 15,000 to 90,000 fish ha−1 in 15,000 fish ha−1 increments to analyze the effect of nitrogen loading on ammonia accumulation and fish production. Minimum dissolved oxygen (DO) concentration was maintained above 3.0 mg O2 L−1 to prevent hypoxia‐induced appetite reduction. Stocking density did not impact survival but decreased average fish harvest weight and increased food conversion ratio (FCR). Gross production increased with stocking density and ranged from 7249 to 35,674 kg ha−1. Average total (TAN) and un‐ionized ammonia (NH3) were not different among stocking densities despite greater nitrogen inputs in ponds with higher feeding rates. Nitrite () and nitrate () concentrations were significantly higher in ponds with higher stocking densities, suggesting that nitrification increased with nitrogen loading. Phytoplankton assimilation of ammonia is the primary ammonia removal process in traditional catfish ponds with modest fish densities and feeding rates. However, in intensively aerated ponds with high feeding rates, nitrification can become an important process for ammonia removal. These data indicate that small earthen hybrid catfish ponds with high aeration capacities can increase catfish production without ammonia accumulating.

Changes in appetite during acute passive intermittent and continuous hypoxemia in postprandial and fasting states: A combined analysis of four laboratory-based randomized crossover trials

Hypoxemia occurs during exposure to high altitude (continuous hypoxemia) or in the context of breathing disorders such as obstructive sleep apnea (OSA; intermittent hypoxemia). Growing evidence demonstrates that hypoxemia induces an anorexigenic effect on appetite; however, few studies have assessed hypoxemia-related reductions in appetite during acute passive exposures and during intermittent hypoxemia. This study thus pooled together four same-single-site randomized crossover trials using simulated models of high altitude (fraction of inspired oxygen = 0.1200, ∼5000 m) and moderate OSA (∼15 hypoxemic cycles per hour, ∼85 oxyhemoglobin saturation). Changes in appetite were evaluated during 6 h of passive normoxia and intermittent or continuous hypoxemia in postprandial or fasting states among healthy young adults (n = 40) and middle-aged individuals living with OSA (n = 7). Our results demonstrate that (1) acute passive intermittent hypoxemia leads to statistically significant, but likely not clinically significant reductions in appetite in the postprandial state, (2) the anorexigenic effect of acute passive hypoxemia on appetite is not consistent across hypoxemic methods and nutritional states, and (3) variations in individual factors may influence appetite responses during normoxia and hypoxemia. These findings indicate that the effect of acute passive hypoxemia on appetite is heterogeneous, particularly across different hypoxemic methods and nutritional states.

Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes.

Metformin is the first-line medication for type 2 diabetes. It is effective and safe, provided some caution is taken in specific populations. In patients with chronic kidney disease, metformin may provide long-term benefits, and it is a first-line therapy for diabetes, but the estimated glomerular filtration rate (eGFR) must be assessed regularly, to minimize the risk for metformin accumulation. When eGFR is 30-60 mL/min/1.73m2, the dose should be reconsidered, and sick-days education provided. Metformin should be discontinued when eGFR falls below 30 mL/min/1.73m2. Metformin accumulation may increase the risk for lactic acidosis if concomitant risk factors for hyperlactataemia (liver or respiratory insufficiency, sepsis, acute heart failure) are present; in these conditions, metformin is contraindicated, even although the available evidence is reassuring. Patients on metformin often complain of gastrointestinal side effects (mainly diarrhoea and nausea) during therapy initiation, but they may sometimes occur after years of stable therapy. These usually resolve if the dose is carefully titrated, or by switching to the extended-release formulation. Patients with obesity may benefit from the significant, although modest, metformin-associated weight loss and appetite reduction. During pregnancy, metformin is associated with a reduction of pregnancy complications, especially in obese women, but some concern remains, because metformin crosses the placenta, and it is associated with a significantly lower mean birth weight than insulin. In the elderly, gastrointestinal tolerability and renal function must be reassessed more often. Vitamin B-12 should be screened regularly in long-time metformin users because metformin may induce clinical vitamin B-12 deficiency.

Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting

BackgroundDietary restrictions or reductions such as fasting for weight loss are often difficult to adhere to due to increased appetite and food cravings. Recently, gastrointestinal delivery of bitter hops has been shown to be effective at reducing appetite in men. Our aim was to determine the effect of a bitter hop extract on appetite and cravings in women, using a 24 h, water-only fast. MethodsThis was a randomized, double-blind, cross-over treatment study. Thirty adult women were recruited and required to fast for 24 h from 1800 h to 1800 h on three occasions and given an ad libitum meal to break each fast. Treatments of either a placebo or one of two doses (high dose; HD: 250 mg or low dose; LD: 125 mg) of a bitter hop-based appetite suppressant (Amarasate®) were given twice per day at 16 and 20 h into the fast. ResultsThe HD and LD treatment groups exhibited a significant (p < 0.05) reduction in appetite and cravings for food when compared to the placebo control. Two participants reported loose stools and one reported heartburn while on the HD treatment, and one participant reported loose stools while on the LD treatment. ConclusionThese data suggest that appetite suppressant co-therapy may be useful in reducing hunger during fasting in women and shows that gastrointestinal delivery of bitter compounds may also be an effective method of reducing cravings for food.This trial received ethical approval from the Northen B New Zealand Human Disability and Ethics committee (Northern B Health and Disability Ethics Committee (2022 EXP 10995) and was prospectively registered with the Australian New Zealand Clinical Trial Registry (ACTRN12622000107729).

BMI, weight change, appetite reduction and cognitive impairment of elderly patients with diabetes

Body weight is related to both diabetes and cognitive impairment; however, the associations between body mass index (BMI) and cognitive impairment have been reported less frequently among diabetes patients. A total of 1355 patients with type 2 diabetes aged ≥ 60 years were included in this study. The Montreal Cognitive Assessment (MoCA) was administered to assess participants’ cognitive status. We collected self-reported body weight, weight loss and appetite loss data using questionnaires. Associations between body weight status (in childhood, midlife age, and late life), weight loss, appetite changes and cognitive impairment were explored using logistic regression. Among the participants, 41.7% exhibited cognitive impairment. Overweight in childhood and late life was associated with cognitive impairment among diabetes patients (OR 2.63, 95% CI 1.52–4.55; OR 1.32, 95% CI 1.03–1.69). Diabetes patients with cognitive impairment were more likely to report a body weight decline and appetite reduction in the past three months (OR 4.18, 95% CI 2.61–6.71; OR 4.41, 95% CI 2.67–7.29). Higher BMI, weight loss, and appetite reduction were positively correlated with cognitive impairment. Given the risk of cognitive impairment, we suggest that body weight and BMI decline should be monitored in patients with diabetes.

Semaglutide in the Treatment of Diabetes and Associated Obesity

Introduction and objective: Diabetes represents one of the most significant healthcare challenges of the 21st century. The disease is frequently asymptomatic, with patients often remaining undiagnosed for extended periods and failing to seek assistance from healthcare professionals. A sedentary lifestyle, excessive caloric intake, and a lack of physical activity contribute to the development of obesity, which in turn leads to carbohydrate metabolism disorders. In this study, we will examine the relationship between diabetes and obesity, and discuss the drug semaglutide, which is used to treat type 2 diabetes and also promotes weight loss. Review methods: Review and summary of research studies available in open-source format on Google Scholar, PubMed. Abbreviated description of the state of knowledge: Numerous clinical studies have demonstrated the efficacy of semaglutide in improving lipid profiles and promoting weight loss. This effect is believed to be mediated by the drug's ability to slow gastric emptying. It is evident that semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, exerts a beneficial effect on carbohydrate parameters and helps to delay the occurrence of complications associated with diabetes. Summary: A review of clinical reports and conducted studies indicates that semaglutide has the potential to enhance parameters that directly or indirectly impact the quality of life of patients with diabetes. However, the utilisation of the aforementioned pharmaceutical is associated with adverse effects, which may impede patient-physician collaboration and potentially precipitate the development of new health complications in patients. One of the effects of semaglutide treatment is a reduction in appetite, which contributes to weight loss. This property of the drug makes it suitable for use in patients with excessive body weight.

Effect of Transcutaneous Electrical Nerve Stimulation of T6 Dermatome on Appetite and Weight Reduction in Obese Individuals: A Pilot Study

Background: Previous work demonstrated the beneficial effect of T6 dermatomal stimulation by the percutaneous method in managing obesity. However, a simple, cost-effective, and feasible intervention stimulating the dermatome can be a potential solution for obesity care. Objective: The objective of this study was to find the effect of transcutaneous electrical nerve stimulation (TENS) of T6 dermatome on appetite and weight loss in obese individuals. Material and Methods: In this prospective single-arm experimental study, 20 obese patients received TENS treatment of T6 dermatome for 30 min, once a week and for 12 weeks. Outcome measures such as appetite level in the visual analog scale (VAS), weight in kg, and basal metabolic index (BMI) in kg/m2 were assessed at baseline, 12 weeks -post-intervention, and at 8 weeks of follow-up. Results: A statistically significant difference in all the variables was found from baseline to 12 weeks of intervention (P &lt; 0.001) and maintained till 8 weeks of follow-up. From pre- to post-treatment, the effect size for appetite reduction was large (&gt;1) while for weight and BMI loss was (0.14, 0.16), respectively small. Additionally, a weak correlation was found between pre- and follow-up appetite and weight loss (r = 0.25, P = 0.294). Conclusions: Twelve weeks of TENS treatment of T6 dermatome showed a positive effect in reducing appetite with sustained reduction up to 8 weeks of follow-up even after completion of the intervention. However, in the absence of dietary modification, TENS treatment was associated with low effect sizes weight and BMI loss.

Management of anti-tuberculosis drug induced xerostomia in completely edentulous patient-A case report

Tuberculosis (TB) is one of the major systemic conditions which is a preventable and curable infection but remains a significant cause of death and reduced quality of life of patients.Weight loss, tiredness and loss of appetite are common symptoms that are even more aggravated in geriatric patients affecting the quality of life of the patient.Edentulism, hyposalivation and dryness of the mouth further contribute to the discomfort in patients wearing dentures that leads to the weight reduction, indigestion and loss of appetite in such patients. Compromised esthetics and speech of the patient just multiply the social trauma and isolation the patient is already facing due to TB.This paper describes a novel method of managing a patient with active TB on Anti Tuberculosis therapy (ATT) reporting symptoms of xerostomia.Completely Edentulous Maxillary and Mandibular Residual Alveolar Ridges: PDI Class II with associated ATT-induced Xerostomia.Split denture with a salivary reservoir in the mandibular denture.Improved aesthetics &amp; speech, improved mastication and reduced weight loss due to denture wearing.Split dentures with artificial saliva can increase the patient's comfort in wearing dentures which overturns the impact of infection significantly and leads to increased quality of life in edentulous patients on ATT.

Efficacy of Herbal Supplementation of Purslane Freeze-dried Juice for Weight Loss: An 8-week Randomized, Double-blind, Placebo-controlled Clinical Trial

Background: Obesity is a condition that has been linked to several ailments. The current investigation is a randomized, double-blind, placebo-controlled clinical experiment to examine how Portulaca oleracea L. tablets affect hunger and Body Mass Index (BMI). Methods: A total of 70 healthy people aged 18 - 65 years old with a BMI &gt;25.0 kg/m² were chosen for an 8-week study. They were randomized into two groups, herbal medicine and placebo. Anthropometry, laboratory tests, and appetite assessment by questionnaire were performed at baseline and the end of the study period. In the end, the data were analyzed. Results: There were significant differences in appetite and BMI (p&lt;0.05) between the two groups after 8 weeks. No serious adverse events occurred in the two groups, and herbal medicine was well tolerated. Purslane juice was found to be well tolerated and could be effective in the reduction of appetite and BMI, either in obese or overweight individuals, following 8 weeks of intervention. Conclusion: The trial indicated the effectiveness of this extract on appetite and BMI. However, long-term investigations with larger populations are needed to determine the tolerability and permanent effectiveness of this natural medicament.

The Role of Microcin B17-Producing Escherichia Coli, Isolated from Patients with Inflammatory Bowel Disease on Rat Intestine

Background: Inflammatory Bowel Disease (IBD) is a chronic gastrointestinal disease, Crohn’s disease (CD) and ulcerative colitis (UC) are two distinct kinds of IBD. Recent researches have linked between Escherichia coli which produce the toxin microcin B17 (E. coli/+mB17) and the development of inflammatory bowel disease (IBD). Objective: This study aimed to demonstrate the relationship between these E. coli isolates and the emergence of IBD in an experimental animal models. Materials and Methods: Twenty female rats, five-weeks-old were divided in to four groups; first group, were orally given E. coli/+mB17 isolated from crohn’s patients stool, the second group rats were orally given E. coli/+mB17 isolated from patients stool with ulcerative colitis, in the third group were orally given E. coli non-producing microcin B17 (E. coli/-mB17) isolated from patients stool with IBD, and the last group received normal saline orally, as control. After fifteen weeks of administration, Blood was drawn for serological tests which include interlukin-10 (IL-10) and tumor necrosis factor-α (TNF-α) and the rats sacrificed for evaluation of histological changes in their intestine. Results: All groups that were administrated bacteria, whether they were toxin producer or not, showed a decrease in their weights with a reduction of appetite. Serological changes observed included an increase in IL-10 level and an increase in TNF-α level in their sera. Regarding the histological examination, there were noticeable histological changes in the large intestines of all rats given bacterial suspension but not in small intestine. Conclusion: All E.coli isolates which were isolated from IBD patients stool (whether it was microcin B17 producing or not) were able to induce inflammatory responses and histological changes in the intestines of rats . Accordingly, other virulence factors (in addition to Microcin B17) may play role in the pathogenesis of IBD.

Obezitede Medikal Tedavi

The main aim of obesity management is to improve health. Weight loss of 5-10% or more provides improvement in obesity and obesityrelated&#x0D; comorbid diseases (Type 2 diabetes mellitus, hypertension, dyslipidemia, fatty liver disease, etc.) as well as an increase in quality&#x0D; of life. As with all chronic diseases, obesity management requires a multidisciplinary approach. Individual treatment should be targeted.&#x0D; Obesity treatment consists of lifestyle changes, medical treatment, and bariatric surgery. Until today, many drugs have worked with&#x0D; the aspect of appetite reduction and energy expenditure through the nervous system. However, many drugs have been withdrawn&#x0D; due to safety concerns. In recent years, drugs with gut-based incretin mechanisms of action have attracted considerable interest.&#x0D; The first approved glucagon-like peptide-1 receptor agonist (GLP-1) analog liraglutide is promising. As a new treatment, the GLP-1&#x0D; analog semaglutide 2.4 mg weekly is approved for the treatment of obesity. Another new treatment, tirzepatide, the first dual GLP-1/&#x0D; glucagon-like peptide-1 receptor agonist (GIP) analog, has achieved up to 20% weight loss in obese patients and has also shown positive&#x0D; cardiovascular outcomes. Although promising, there is no comparative study of new effective obesity drugs with bariatric surgery,&#x0D; which is currently known as the most effective method, with weight loss up to 25%. Today, as the pathophysiogenesis of obesity is better&#x0D; understood, newer, safer molecules will continue to emerge. In this review, current information about the current and future medical&#x0D; treatments for obesity will be discussed.

Food go/no-go training alters neural circuits for food evaluation for appetite reduction

Food go/no-go training has been traditionally categorized as a type of inhibitory training that decreases the desire for high-calorie food consumption. This training requires participants to either respond or withhold their responses to presented items with go cues or food items with no-go cues, respectively. Recent findings have suggested that this training may devalue food items associated with no-go cues instead of facilitating inhibitory control, leading to reduced food consumption. We thus hypothesized that food go/no-go training would alter the brain response to food items with no-go cues in food evaluation regions. To examine this hypothesis, we conducted a repeated measures functional magnetic resonance imaging using food images in healthy participants, who underwent 3 weeks of food go/no-go training (n = 26) using high- and low-calorie food items paired with no-go cues (no-go food) and go cues (go food), respectively, and control training (n = 24). The food go/no-go training reduced the ratings for the desire to eat no-go foods and increased the ratings for go foods. The reduction in no-go food rating was positively associated with a decrease in daily snack intake. The neural responses in the food evaluation regions increased for go foods. Moreover, the functional connectivity of those regions was altered. The food go/no-go training did not decrease impulsivity traits or increase restrained eating, which are associated with inhibitory control. Overall, food go/no-go training influenced the brain regions associated with food evaluation, thus devaluating no-go foods and reducing the daily snack intake. Accordingly, food go/no-go training could promote healthier food choices.

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy. Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.

FRI004 Sex Differences In Oxytocin And Arginine-Vasopressin Levels Around A Standardized Meal In Adults With Obesity

Abstract Disclosure: M. Wronski: None. J.T. Sanislow: None. K. Holman: None. J. Gydus: None. M. Muhammed: None. S. Smith: None. E. Asanza: None. E.R. Golden: None. N. Hadaway: None. S. Ehrlich: None. A. Aulinas Maso: None. L. Kerem: None. J.M. Davis: None. H.P. Nazarloo: None. S. Carter: None. F. Plessow: None. E.A. Lawson: None. Objective: Oxytocin (OXT) and arginine-vasopressin (AVP) are neurohormones involved in metabolism that are regulated by gonadal steroid levels. OXT tends to be higher in healthy-weight females than males; levels decrease following a meal with an associated reduction in appetite. In contrast, AVP tends to be lower in healthy-weight females than males; post-prandial AVP response has not been examined. OXT and AVP levels in response to feeding and the impact of sex are important to study in individuals with obesity to improve our understanding of disease pathophysiology and advance treatment. We investigated peripheral OXT and AVP levels in female and male adults with obesity fasting and at three post-prandial time points (TP). Methods: The diverse study sample of 56 non-diabetic adults with obesity (35.71% non-White, 19.64% Hispanic) included 30 premenopausal females and 26 males (age: mean ± SEM = 33.73 ± 0.83 years, range = 18.60 - 45.71 years; BMI: 36.77 ± 0.66 kg/m2, 30.20 - 50.60 kg/m2). We tested sex differences in age and BMI using two-samples t-tests. Plasma samples were collected fasting and 30, 60, and 120 minutes (TP) after a standardized ∼500 kcal meal to measure OXT and AVP levels (using enzyme-linked immunosorbent assays). OXT and AVP levels deviating &amp;gt;3*SD from the hormone-, sex-, and TP-specific mean were excluded prior to log-transformation to approximate normality. Sex differences and meal-related dynamics in OXT and AVP levels were examined using two random-intercept linear mixed effects models with predictors sex, TP, and sex-x-TP interaction, covarying for BMI (false discovery rate across both models). Results: Age and BMI did not differ between sexes (ps ≥ 0.354). Across TPs, female sex significantly predicted lower OXT (F(1,53) = 4.90, FDR-q = 0.031, partial eta squared = 0.08, adjusted mean ± SEM females = 273.95 ± 1.12 pg/mL versus males = 397.61 ± 1.13 pg/mL) and lower AVP (F(1,52) = 5.04, FDR-q = 0.031, partial eta squared = 0.09, adjusted mean ± SEM females = 79.77 ± 1.21 pg/mL versus males = 149.39 ± 1.22 pg/mL). TP and sex-x-TP interaction effects were nonsignificant. Conclusion: In this first study to investigate sex differences and meal-dependent changes in OXT and AVP levels in adults with obesity, we found that levels of both neurohormones were lower in females than males. In contrast to our previous finding of a post-prandial decrease in OXT, associated with change in appetite in healthy-weight females, there was no impact of food intake on OXT or AVP levels in adults with obesity. Our data indicate that in obesity, OXT and AVP levels are sexually dimorphic and postprandial dynamics may be dysregulated. Presentation: Friday, June 16, 2023

Evaluation of Different Dietary Strategies on Body Composition in Individuals with Obesity

Obesity is a global health challenge. This study evaluated the effects of 4 dietary strategies on the body composition. Where 200 volunteers from southern Brazil were evaluated, 100 men and 100 women, between the ages of 20 and 50 and with a body mass index (BMI) equal to or greater than 30 kg/m2. Divided into 4 groups of dietary interventions: G1 – control diet, G2 – low-carbohydrate high-fat (LCHF), G3 – control diet with intermittent fasting (IF), G4 – low-carbohydrate high-fat with intermittent fasting (LCHF + IF). For 6 months, patients were monitored according to their body weight (BW), BMI, waist circumference (WC), body fat percentage (%BF), lean body mass (LBM), systolic blood pressure (SBP), blood glucose, and answered an assessment of adherence and satisfaction. The data was submitted to mixed linear model and multivariate analysis. No significant reduction in BW was observed, but all groups showed a reduction in WC. The caloric restriction with carbohydrate reduction (LCHF) and the application of IF caused a reduction in WC and %BF and resulted in improvement in glucose and SBP. Diets that include the application of LCHF (G2) and the use of IF (G4) show faster results and can end up generating more motivation to continue the diet. The application of an LCHF diet with IF protocols (G4) shows that there is indeed a potentiation of the results through IF application. IF was associated with the patients’ reduction in appetite, improved mood and well-being, and intention to continue the diet.